This article has an accompanying continuing education activity on page e13. Learning Objective: Upon completion of this exercise, successful learners will be able to indicate the most appropriate treatment for patients with Barrett's esophagus.
See Covering the Cover synopsis on page 1953.
BACKGROUND & AIMS:
The incidence of Barrett's esophagus and esophageal adenocarcinoma has increased despite surveillance of patients with Barrett's esophagus. Limited data indicate that nonsteroidal anti-inflammatory drug (NSAID) and statin use reduce the risk for esophageal adenocarcinoma. We investigated whether NSAID or statin use reduces the risk of neoplastic progression from Barrett's esophagus. METHODS: We performed a prospective study of 570 patients with Barrett's esophagus at 3 academic and 12 regional Dutch hospitals. Information on medication use was collected in patient interviews at each surveillance visit and cross-checked with pharmacy records. Patients completed a questionnaire about use of over-the-counter medication. Incident cases of high-grade dysplasia and adenocarcinoma were identified during the follow-up period. RESULTS: During a median follow-up period of 4.5 years, 38 patients (7%) developed high-grade dysplasia or adenocarcinoma. After Barrett's esophagus had been diagnosed, 318 patients (56%) used NSAIDs for a median duration of 2 months, 161 (28%) used aspirin for a median duration of 5 years, 209 (37%) used statins for a median duration of 5 years, and 107 (19%) used NSAIDs and statins. NSAID and statin use were each associated with a reduced risk of neoplastic progression (hazard ratio [HR] , 0.47; P ϭ .030 and HR, 0.46; P ϭ .048, respectively). Use of a combination of NSAIDs and statins increased the protective effect (HR, 0.22; P ϭ .028). CONCLUSIONS: NSAID and statin use reduce the risk of neoplastic progression in patients with Barrett's esophagus. Use of a combination of NSAIDs and statins appears to have an additive protective effect.
Keywords: Gastroesophageal Reflux Disease; Chemoprevention; Cancer Risk; Tumor. B arrett's esophagus (BE) is a premalignant condition in which the normal squamous epithelium of the distal esophagus is replaced by metaplastic columnar epithelium containing goblet cells. 1 It is a relatively common condition with an estimated prevalence of 1%-2% in Western countries. [2] [3] [4] Chronic gastroesophageal reflux disease appears to play a central role in the development of Barrett's epithelium, and approximately 10% of patients with gastroesophageal reflux disease will eventually develop BE. 5 Barrett's patients have a 30-to 125-fold increased risk for developing esophageal adenocarcinoma (EAC) with a yearly incidence of approximately 0.5%. 6, 7 Unfortunately, it is not yet possible to predict which patients have the highest risk of developing EAC. As a result endoscopic follow-up is recommended in all BE patients. 8, 9 Strategies to prevent the development of adenocarcinoma in BE have focused primarily on reversal of Barrett's epithelium and early detection of adenocarcinoma during surveillance. However, despite surveillance of Barrett's patients, the incidence of EAC has been rising rapidly. 10, 11 Therefore, new strategies are necessary to prevent the development of adenocarcinoma. Multiple studies have given support to the use of chemoprevention in the treatment of several cancers including esophageal cancer. 12 Observational studies have suggested that use of nonsteroidal anti-inflammatory drugs (NSAIDs) and statins may reduce the risk of neoplastic progression in BE patients. [13] [14] [15] Chemoprevention with a combination of NSAIDs and statins might provide an even stronger risk reduction. 16, 17 However only limited studies have investigated the effect of NSAID and statin use on the develop-ment of high-grade dysplasia (HGD) and EAC in BE. Most studies included only small numbers of patients and lacked clinical information. To our knowledge, no large prospective cohort studies have been published investigating the combination of NSAID and statin use. The aim of this study was therefore to investigate whether use of NSAIDs and statins reduces the risk of neoplastic progression in BE patients.
Patients and Methods

Study Design
We conducted a multicenter prospective cohort study in 3 university medical centers and 12 regional hospitals throughout The Netherlands (Appendix 1). Between November 2003 and December 2004, 786 patients were included, presenting at the endoscopy unit with known or newly diagnosed BE. We excluded patients with BE shorter than 2 cm, patients younger than 18 years, and patients with HGD or EAC in the past or at index endoscopy. There were no restrictions regarding medication use. The endoscopic BE diagnosis was confirmed in all patients by the presence of intestinal metaplasia. Incident cases of HGD or EAC were identified during follow-up. Two hundred sixteen patients dropped out of the study because of severe comorbidity (n ϭ 30), death of causes unrelated to BE (n ϭ 18), migration (n ϭ 10), refusal of participation (n ϭ 155), or neoplastic progression within 9 months of inclusion (n ϭ 3). The patients who dropped out were older than those still participating in surveillance (median, 66.4 years vs 60.4 years, respectively). However, there were no differences in gender, BE length, baseline histology, and medication use.
Endoscopic Surveillance
A central trial coordinator controlled the follow-up of all BE patients participating in this study. Surveillance was performed according to the American College of Gastroenterology guidelines: patients without dysplasia were seen for follow-up gastroscopy every 3 years, and patients with low-grade dysplasia (LGD) were seen every year. 18 Patients who developed HGD or EAC during follow-up were considered to have reached an end point and received appropriate endoscopic or surgical treatment. The endoscopies were performed by experienced gastroenterologist at the 15 participating hospitals, according to a standardized protocol. During gastroscopy, endoscopic landmarks such as the diaphragm, gastroesophageal junction, and squamocolumnar junction were determined. We also documented the presence and grade of esophagitis according to the Los Angeles Classification and reported mucosal abnormalities including nodules, ulcers, and erosions. 19 Targeted biopsy samples were taken from mucosal abnormalities, and, in addition, 4-quadrant biopsy samples were taken every 2 cm from the most distal to the most proximal part of the Barrett's epithelium.
At each surveillance visit, patients filled out a questionnaire on demographic factors; length; weight; former and current smoking habits; former and current alcohol use; time of BE diagnosis; relatives with BE or EAC; symptoms such as reflux, regurgitation, and dysphagia; and medication use. The endoscopic findings and clinical data were prospectively recorded in individual case record forms and processed in a central database by the trial coordinator.
Histologic Examination
Biopsy specimens were fixed with 10% formalin and embedded in paraffin. Four-micrometer serial sections were cut and stained with H&E. The histologic slides were first examined by a local pathologist at the participating hospital. Dysplasia was graded according to the consensus criteria of 1988, with adjustments as proposed in 2001. 20, 21 Previous studies have shown high interobserver variability in the interpretation of dysplasia in BE. 22 All biopsy specimens were therefore reviewed by 1 or 2 expert gastrointestinal pathologists. These expert pathologists were blinded to the diagnosis of the local pathologist. A final diagnosis was made only if at least 2 pathologists agreed on the grade of dysplasia. If there was disagreement between the pathologists, a panel of expert pathologists reviewed the slides as well, and the final diagnosis was made on the basis of consensus agreement.
Medication Use
Information on medication use after BE had been diagnosed was collected in patient interviews with each surveillance visit. In addition, patients filled out a questionnaire on their use of over-the-counter medication. This questionnaire included items on NSAID use without prescription, such as medication name, dosage, and frequency of use. The information collected in both the patient interviews and questionnaire was crosschecked using pharmacy records. All patients gave written consent for requesting their complete pharmacy records. The pharmacy records contain information on all delivered medications including dose, time of prescription, and over-the-counter medication. The pharmacies are legally required to keep these pharmacy records for at least 15 years. Using the pharmacy records, we recorded filled prescriptions for proton pump inhibitors (PPIs) (omeprazole, lansoprazole, rabeprazole, pantoprazole, esomeprazole), nonselective NSAIDs (nsNSAIDs) (acetylsalicylic acid Ͼ325 mg per day, carbasalate calcium Ͼ325 mg per day, diclofenac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, aceclofenac, dexibrufen, dexketoprofen, fenylbutazon, piroxicam, sulindac, tolmetin), cyclooxygenase (COX)-2 inhibitors (celecoxib, rofecoxib, etoricoxib, meloxicam), low-dose aspirin (acetylsalicylic acid Յ100 mg per day, carbasalate calcium Յ100 mg per day), and statins (simvastatin, lovastatin, atorvastatin, fluvastatin, pravastatin) from the time of BE diagnosis to the most recent endoscopy or to the endoscopy that resulted in the diagnosis of HGD or EAC. For each patient, the total duration of filled prescriptions for PPIs, NSAIDs, aspirin, and statins was calculated by adding the duration of individual prescriptions and subtracting overlap in dates. Patients were classified as users of PPIs, NSAIDs, aspirin, or statins after the pharmacy had provided medication for at least 1 month to ensure that patients with single-use were not identified as users.
Ethics
The study protocol was approved by the Medical Ethics Committee of the Erasmus University Medical Center and by the local medical ethics committees of all participating hospitals. Before the first gastroscopy, written informed consent was obtained from all patients. Patients also gave written informed consent to obtain their pharmacy record.
Statistical Analysis
The incidence rate of neoplastic progression was calculated by dividing the number of patients with HGD or EAC by the total person-years of follow-up in the study. The effect of NSAID, aspirin, and statin use on the risk of neoplastic progression was estimated in Cox proportional hazards models. Follow-up time was defined as the time from inclusion in the study to the most recent surveillance endoscopy or to the endoscopy that resulted in a diagnosis of HGD or EAC. Incident cases of HGD or EAC were defined as the development of HGD or EAC at least 9 months after the index endoscopy. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI). The exposure of interest was use of NSAIDs, aspirin, and statins after BE had been diagnosed. The 5-year cumulative incidence of neoplastic progression was estimated using Kaplan-Meier curves. In multivariable Cox proportional hazards models, we calculated HR and 95% CI, adjusted for age, gender, BE length, baseline histology, and use of other medications. Several cumulative durations of medication use were evaluated to investigate a possible duration-response relationship. To assess how users of NSAIDs and statins differed from nonusers, we evaluated the patient characteristics for each exposure of interest. Mann-Whitney-Wilcoxon tests were used for continuous variables and 2 tests for categorical variables. In addition, we constructed Kaplan-Meier curves of the cumulative incidence of neoplastic progression stratified by medication use, and we compared these curves using the log-rank test for equality. Two-sided P values Ͻ .05 were considered to be statistically significant. Data were analysed using SPSS Statistics (version 17.0; SPSS Inc, Chicago, IL).
Results
Patient Characteristics
A total of 570 BE patients was included in this study. The median age at the time of inclusion was 60.4 years (interquartile range, 14.5), and 412 (72%) patients were of male sex. Patients were followed for a median duration of 4.5 years (interquartile range, 1.8). After inclusion in the study, 26 patients developed HGD, and another 12 patients developed EAC during a total follow-up period of 2738 patient years. The incidence rate of HGD and EAC together was 1.4 per 100 patient-years, and the incidence rate of EAC alone was 0.4 per 100 patientyears. The risk of neoplastic progression significantly increased with age. Other significant risk factors for developing HGD or EAC during follow-up were long Barrett's segment and LGD (Table 1) .
Medication Use
After BE had been diagnosed, 562 (99%) patients were prescribed PPIs for median duration of 9.0 years; 318 (56%) patients used NSAIDs for a median duration of 2 months, either prescribed or as over-the-counter medication; 161 (28%) patients were prescribed aspirin for a median duration of 5.4 years; and 209 (37%) patients were prescribed statins for a median duration of 5.3 years. Of the patients using NSAIDs, 87 (15%) patients were prescribed COX-2 inhibitors, and 289 (51%) patients used nsNSAIDs. Of the 532 patients without neoplastic progression, 303 (57%) patients used NSAIDs, 153 (29%) patients used aspirin, and 200 (38%) patients used statins. Of the 38 patients who developed HGD or EAC during follow-up, 15 (40%) patients used NSAIDs, 8 (21%) patients used aspirin, and 9 (24%) patients used statins ( Table 2) .
Effect of NSAID Use
In an unadjusted Cox proportional hazard model, NSAID use was associated with a reduced risk of neoplastic progression in patients with BE (HR, 0.51; 95% CI: 0.27-0.99). NSAID use remained associated with a reduced risk of developing HGD or EAC (HR, 0.47; 95% CI: 0.24 -0.93) after adjustment for age, gender, BE length, baseline histology, and use of other medications. This effect of NSAID use was the same for men and woman and for patients younger and older than 60 years. When considering use of COX-2 inhibitors and nsNSAIDs separately, only use of nsNSAIDs was associated with a significantly reduced risk of neoplastic progression in BE patients (HR, 0.43; 95% CI: 0.22-0.88). Figure 1A shows the cumulative incidence of neoplastic progression during follow-up, stratified by NSAID use. Patients who did not use NSAIDs had a higher risk of developing HGD or EAC than patients using NSAIDs (P ϭ .041).
To investigate a possible duration-response relationship, we evaluated different cumulative durations of NSAID use. NSAID use for more than 2 months was 
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associated with a trend toward a lower risk of neoplastic progression than NSAID use for 2 months or less (Table  3) . To assess how users of NSAIDs differed from nonusers, we evaluated the patient characteristics of both groups. NSAID users were slightly younger and had a higher body mass index than patients who did not use NSAIDs. There were no differences in gender, year of BE diagnosis, BE length, baseline histology, and duration of follow-up (Table 4) .
Effect of Low-Dose Aspirin Use
Use of low-dose aspirin did not change the risk of neoplastic progression in an unadjusted model (HR, 0.67; 95% CI: 0.31-1.46) and in a model that adjusted for age, gender, BE length, baseline histology, and use of other medication (HR, 0.66; 95% CI: 0.27-1.65). Although the effect of aspirin use was not significant, the HR pointed in the direction of a protective effect. 
Effect of Statin Use
In an unadjusted model, statin use was associated with a trend toward a reduced risk of neoplastic progression in BE patients (HR, 0.52; 95% CI: 0.25-1.09). Figure  1B shows the cumulative incidence of HGD and EAC in BE patients during follow-up, stratified by statin use. A trend was seen toward a higher risk of neoplastic progression in patients who did not use statins than in patients using statins (P ϭ .079). In a multivariable model, statin use was associated with a significantly reduced risk of neoplastic progression (HR, 0.46; 95% CI: 0.21-0.99) after adjustment for age, gender, BE length, baseline histology, and use of other medications. This effect of statin use was only seen in men and in patients older than 60 years of age.
To investigate a possible duration-response relationship, we evaluated different cumulative durations of statin use. There was no difference in the effect of statin use for more than 5 years and statin use for 5 years or less (Table 3) . However, most patients used statins for several years. To assess how users of statins differed from nonusers, we evaluated the patient characteristics of both groups. Statin users were older than patients not using statins. However, there were no differences in gender, body mass index, year of BE diagnosis, BE length, baseline histology, and duration of follow-up (Table 4) .
Effect of NSAID and Statin Use
After BE had been diagnosed, 150 (26%) patients used neither NSAIDs nor statins, 211 (37%) patients used only NSAIDs, 102 (18%) patients used only statins, and 107 (19%) patients used both NSAIDs and statins (Table  5 ). In an unadjusted Cox regression model, use of NSAIDs or statins was associated with a trend toward a lower risk of neoplastic progression than use of neither NSAIDs nor statins (HR, 0.48; 95% CI: 0.23-1.01 for NSAIDs alone and HR, 0.48; 95% CI: 0.19-1.21 for statins alone). Use of both NSAIDs and statins was associated with an even lower risk of developing HGD or EAC during follow-up (HR, 0.24; 95% CI: 0.07-0.82). In a multivariable model, use of both NSAIDs and statins was also associated with an additive protective effect (HR, 0.22; 95% CI: 0.06-0.85), after adjusting for age, gender, BE length, baseline histology, and use of PPIs. Figure 1C shows the cumulative incidence of neoplastic progression in BE patients during follow-up, stratified by both NSAID and statin use. The cumulative incidence of HGD or EAC was lower in patients using an NSAID or statin than in patients using neither (log rank P ϭ .048 for NSAIDs alone and log rank P ϭ .113 for statins alone). In patients using both NSAIDs and statins, the cumulative incidence of neoplastic progression was even lower (log rank, P ϭ .014).
Discussion
In this large prospective cohort study, NSAID and statin use were associated with 50% reduction in the risk of neoplastic progression in patients with BE. Use of both NSAIDs and statins had an additive protective effect and was associated with approximately 75% reduction in the risk of developing HGD or EAC. These associations were independent of age, gender, BE length, baseline histology, and use of other medication.
In our study, reduction in the risk of neoplastic progression with NSAID use appeared to be related to duration of medication use. However, patients used NSAIDs for a relatively short median duration of 2 months raising concerns of uncontrolled confounding. In addition, use of low-dose aspirin was associated with a smaller, nonsignificant reduction in the risk of neoplastic progression than use of NSAIDs, indicating a dose-response relationship. The presence of duration-response and dose-response relationship supports a causal association between NSAID use and the risk of neoplastic progression in BE. Although chemoprevention with NSAIDs seems to be more effective than chemoprevention with low-dose aspirin, use of NSAIDs will also lead to more serious adverse effects.
The results of our study are consistent with previous published studies investigating the effect of NSAID use on the risk of developing EAC in BE patients. A casecontrol study with 114 EAC patients and 382 BE patients observed that NSAID use was significantly more prevalent in BE patients (38%) than in EAC patients (26%) (P ϭ .02). 23 Furthermore, in a prospective cohort study with 350 BE patients, current users of NSAIDs were at lower risk for developing EAC than never users of NSAIDs (HR, 0.20; 95% CI: 0.10-0.41). 15 Neither of these studies investigated concomitant PPI or statin use. In a more recent observational study with 344 BE patients, NSAID use was associated with a nonsignificant trend toward lower incidence of HGD or EAC (HR, 0.56; 95% CI: 0.27-1.18). 24 The same study group also performed a case-control study with 116 EAC patients and 696 matched BE pa- tients, which confirmed that NSAID use was significantly associated with a reduced risk of EAC (incidence density ratio, 0.64; 95% CI: 0.42-0.97). 13 Previous studies have also investigated the working mechanism of NSAIDs in chemoprevention. NSAIDs inhibit the COX enzymes COX-1 and COX-2. COX-1 is constitutively expressed in human tissue, whereas COX-2 expression is induced in response to cytokines, growth factors, and mitogens. Inhibition of COX-2 restores apoptosis, inhibits cell growth, decreases cell proliferation, and inhibits angiogenesis in human tissue. 25 In Barrett's patients, inhibition of COX enzymes by NSAIDs may therefore lead to a decreased risk of developing HGD or adenocarcinoma.
Statin use was also associated with a reduced risk of neoplastic progression in our study. Only 2 previous studies have investigated the effect of statin use in BE patients. In a first observational study, statin use did not affect the risk of developing dysplasia or EAC (HR, 0.73; 95% CI: 0.30-1.78), but this study was underpowered with only 87 patients using statins. 24 The results of our study were consistent with the results of a further case-control study in which statin use reduced the risk of EAC (incidence density ratio, 0.55; 95% CI: 0.36-0.86). 13 The patients included in this study were veterans receiving care in the Veterans' Affairs health care system. These patients were therefore more likely to be of male sex and relatively old age than the total BE population. This may limit the generalizability of these results.
The working mechanism of statins in chemoprevention has also been investigated in previous studies. Statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in the biosynthesis of cholesterol. Although this is the most appreciated biologic action, there are several other import roles of statins. Farnesyl and geranylgeranyl are formed in the cholesterol biosynthesis pathway and are essential for the activation of intracellular proteins though prenylation. Several important proteins involved in intracellular signalling such as Ras, Rho, and Rac are dependent on prenylation. Ras is the activator of the extracellular signalregulated kinase, mitogen-activated pathway and possibly the activator of the Akt pathway as well. Both cascades provide cell proliferation and cell survival signals in human cells. As a result, statins may inhibit proliferation and induce apoptosis in Barrett's epithelium leading to a reduced risk of neoplastic progression. 14, 26, 27 In the current study, use of both NSAIDs and statins provided a stronger risk reduction than use of NSAIDs or statins alone. This is the first study investigating the effect of both NSAID and statin use on the risk of neoplastic progression in BE. A previous study in patients with colorectal cancer also demonstrated that chemoprevention with the combination of low-dose aspirin and statins provided a stronger risk reduction than either of the single drugs. 16 Several in vitro studies have investigated the effect of chemoprevention with a combination of NSAIDs and statins. These studies have demonstrated synergistic effects of NSAIDs and statins in inhibition of cell growth and induction of apoptosis in cancer cells. How NSAIDs and statins work in a synergistic fashion is largely unresolved. 16, 17 This study has several strengths including the large sample size of BE patients and long follow-up time. All patients presenting with BE at the endoscopy unit of 3 academic and 12 regional hospitals were included in this study. As a result, our cohort is representative for the total Barrett's population in The Netherlands. The incidence of EAC during follow-up was 0.4 per 100 patient-year, which is equal to the incidence reported in most studies and which supports that our population is representative for the Dutch BE population.
There were strict criteria for BE diagnosis and for inclusion in the study. In addition, there was a stringent follow-up scheme, a standardized endoscopy protocol, and a standardized biopsy protocol. All biopsy samples were reviewed by at least 2 pathologists to obtain a diagnosis on the basis of consensus. During follow-up, clinical information was collected prospectively and recorded in a central computerized database by the trial coordinator.
Information on medication use was collected prospectively, and patients also filled out a questionnaire on their use of over-the-counter medication. All information on medication use was cross-checked using pharmacy records. Because PPI use is one of the mainstays in the treatment of BE patients, it may act as a possible confounder. Therefore, we collected detailed information on PPI use as well.
Our study also has some limitations. Because this is an observational study, we cannot exclude uncontrolled confounding. However, we have collected much information on potential confounding factors during follow-up, and we corrected for these factors in the final analysis. Unfortunately, we didn't have information on the indication of NSAID and statin use. As a result, we were not able to adjust for this possible confounder. Users of NSAIDs and statins may have differed in other ways from other BE patients than in the use of these drugs. To assess how users of NSAIDs and statins differed from nonusers, we evaluated the patient characteristics for each exposure of interest. NSAIDs users were slightly younger and statin users were slightly older than other BE patients, but, otherwise, there were no major differences. Because we adjusted for age in our models, differences between users and nonusers cannot completely explain the effect of NSAIDs and statins observed in this study.
Despite the large sample size of this cohort, the number of events was small in some strata of exposure, limiting the interpretation. This was especially the case when looking at the effect of treatment duration and the interaction between NSAID and statin use. In addition, patients were informed about any changes seen during endoscopy or histologic assessment. In theory, this may have influenced their compliance or lifestyle.
In conclusion, this large prospective cohort study shows that use of NSAIDs and statins is associated with a significantly reduced risk of neoplastic progression in patients with BE. Use of both NSAIDs and statins appears to have an additive protective effect. As a result, chemoprevention with NSAIDs and statins may have a role in the treatment of patients with BE.
